| dc.contributor.author | Erfan, Gamze | |
| dc.contributor.author | Carrera, Cristina | |
| dc.contributor.author | Malvehy, Josep | |
| dc.contributor.author | Puig, Susana | |
| dc.date.accessioned | 2022-05-11T14:37:19Z | |
| dc.date.available | 2022-05-11T14:37:19Z | |
| dc.date.issued | 2017 | |
| dc.identifier.issn | 0001-5555 | |
| dc.identifier.issn | 1651-2057 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.11776/8656 | |
| dc.description.abstract | [No Abstract Available] | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Acta Dermato-Venereologica | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Metastatic Melanoma | en_US |
| dc.subject | Mek Inhibitors | en_US |
| dc.subject | Combination | en_US |
| dc.subject | Vemurafenib | en_US |
| dc.subject | Toxicities | en_US |
| dc.subject | Therapy | en_US |
| dc.subject | Management | en_US |
| dc.title | Cutaneous Side Effects of Single Versus Combined BRAF Inhibitors: A Comment to Erfan et al. Reply | en_US |
| dc.type | editorialMaterial | en_US |
| dc.relation.ispartof | Acta Dermato-Venereologica | en_US |
| dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıkları Ana Bilim Dalı | en_US |
| dc.authorid | 0000-0003-1608-8820 | |
| dc.authorid | 0000-0003-0000-5568 | |
| dc.identifier.volume | 97 | en_US |
| dc.identifier.issue | 10 | en_US |
| dc.identifier.startpage | 1267 | en_US |
| dc.identifier.endpage | 1268 | en_US |
| dc.institutionauthor | Erfan, Gamze | |
| dc.relation.publicationcategory | Diğer | en_US |
| dc.authorwosid | CARRERA, CRISTINA/N-1887-2019 | |
| dc.authorwosid | Erfan, Gamze/W-8139-2018 | |
| dc.identifier.wos | WOS:000419735400028 | en_US |
